The fusion protein PML/RARA, associated with acute promyelocytic leukemia behaves as an abnormal retinoic acid (RA) receptor with altered transactivation properties but is still inducible by RA. The chimeric protein is thought to promote leukemogenesis but also paradoxically to mediate the sensitivity to ATRA of APL cells. This has been supported by works reporting that in vitro ATRA resistance is characterized by defects in the RARA/E-domain of PML/RARA. In the present report, we identified a new mutation in the E domain of PML/RARA which is associated with a RA-resistant subline of NB4 cells; NB4-R2. This mutation, identical to the Gln411 mutation found in HL60-R, changes the amino acid Gln903 to an in-phase stop codon, generating a truncated form of PML/RARA which has lost 52 amino acids at its C-terminal end. We have studied the effect of the truncated PML/RARA protein on PML NB formation and RARA and PML/RARA transcriptional activity. We show here that the fusion mutant exerts a dominant negative effect on wild-type PML, PML/RARA and RARA transcription activity. These findings highlight the important role of the RARA E-domain of PML/RARA in mediating RA sensitivity in APL cells. Leukemia (2000) 14, 255-261.
Introduction
Retinoids are vitamin A derivatives that exert pleiotropic effects in vertebrates. Their actions are mediated by two classes of ligand-dependent transactivation factors belonging to the nuclear receptor superfamily: the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). On the basis of homology with other members of this superfamily, the protein structure of RARs and RXRs comprises six discrete functional domains (A-F). The amino-terminal region (A/B) exerts a ligand-independent transactivation function (AF-1). The C region is highly conserved and contains the DNA-binding domain (DBD) . The E region, also highly conserved, exerts the dimerization, ligand-binding and ligand-dependent transactivation functions (AF-2) (for recent review see Ref. 1) .
Hematopoietic malignancies are often associated with chromosomal rearrangements and it has been shown that acute promyelocytic leukemia (APL) is associated with a reciprocal translocation event, t (15;17) , between PML on chromosome 15 and retinoic acid receptor alpha (RARA) on chromosome 17, leading to the expression of a chimeric protein PML/RARA. 2, 3 Strong evidence implicating PML/RARA protein in leukemogenesis comes from the study of expression of PML/RARA in transgenic mice resulting in a defect in myelopoiesis. 4, 5 It has been shown that PML/RARA retains most functional domains of RARA and behaves as an abnormal RA receptor with altered transactivation properties in comparison to RARA. 6, 7 Immunohistochemical studies have shown that PML is localized in punctate nuclear structures called PML nuclear bodies (PML NBs) which are disrupted in PML/RARAexpressing cells in a retinoic acid reversible manner, 8, 9 suggesting that alteration of the normal function of PML contributes to the physiopathology of APL.
Biological responses induced by retinoids are currently used therapeutically in a variety of disease. 10, 11 APL cells are specifically sensitive to all-trans retinoic acid (ATRA) leading to the differentiation of the leukemic clone and remission of APL patients. 12, 13 Although complete remission can be achieved in APL patients through ATRA treatment, ATRA-resistant relapse occurs in most patients treated with ATRA alone. The mechanisms that promote the resistance are still not understood. However, several explanations have been proposed to describe the ATRA-resistant phenotype, including increasing ATRA catabolism due to elevated levels of cytosolic retinoid binding proteins (CRABP).
14 The fact that in several cases, leukemic blasts from ATRA-resistant APL patients have been reported to have a remarkably decreased sensitivity in vitro, suggests that in some cases ATRA resistance could be due to genetic defects in the retinoid signalling pathway. Such defects have been characterized as point mutations in PML/RARA for NB4 resistant subclones 15, 16 or in some patients with ATRA-resistant APL cells. 17, 18 Several years ago, we isolated a maturation sensitive cell line (NB4) from the bone marrow of an APL patient in relapse. 19 From the same sample, we also isolated numerous leukemic subclones that were refractory to ATRA. Resistant cell lines, in addition to the t(15;17), shared with NB4 various karyotypic markers, suggesting that they were derived from the same APL clone. 20 Resistant cells fell into two categories, classed as NB4-R1 and NB4-R2. The NB4-R1 cells do respond to ATRA but do not mature. This R1-type defect can be rescued by retinoid and cAMP signalling cross-talk. The NB4-R2 cells show a defect in RA signalling and consequently cAMP and RA signalling cross-talk does not operate. 21 We previously established that the NB4-R2 cell line bears the t(15;17) translocation and expresses normal levels of PML, RARA, RXRA and PML/RARA mRNA similar to the parental NB4 cell line. Although the chimeric protein was not detectable using an antibody directed against the F region of RARA, immunofluorescence studies performed on these cells using a PML antibody showed a micropunctate staining pattern, characteristic of the presence of the PML/RARA fusion protein. 22 In addition, using a PML antibody we were unable to detect the PML/RARA fusion protein at the expected size but instead we detected some new PML-related polypeptides of lower molecular weight. 22 To characterize further the resistant phenotype of the NB4-R2 cell line we investigate the presence of a mutation in the RARA moiety of the fusion protein PML/RARA. In this study, we show that the NB4 resistant subclone, NB4-R2, expresses a mutated form of PML/RARA. We identify a mutation at the codon Gln903 to an in-phase stop codon in the E domain of the RARA moiety, leading to expression of a truncated PML/RARA. To investigate the property of this truncated PML/RARA, we recreate the mutation and study its effect on PML NB formation and RARA and PML/RARA transcriptional activity. We show here that the fusion mutant exerts a dominant negative effect on wild-type PML, PML/RARA and RARA transcription activity.
Materials and methods

Sequence analysis
Total RNA from NB4 and NB4-R2 cells was purified and PML/RARA-specific mRNA was isolated using Dynal magnetic beads (M-280 streptavidin) coupled to a biotinylated PML/RARA oligonucleotide (specific for the sequence at the recombination site). This mRNA preparation was used for RT-PCR with oligo(dN)6 as primer and AMV reverse transcriptase at 42°C for 60 min. 1/20 of the RT reaction was used for PCR amplification with the primers R2L (5ЈCTGCCC-CTGGAGATGGATGAT3Ј) and R2H (5ЈGCGGAGGGCGAG-GGCTGTGTC3Ј) and the following conditions: 5 min at 95°C, cycle 1 min 95°C, 2 min 65°C, 1 min 30 s 72°C, and then 10 min 72°C. The PCR product was gel isolated and cloned into the pCRTM2.1 AT sequencing vector. Clones were selected and PCR-tested for the presence of the insert. Positive clones were selected, plasmids were purified from these clones and cDNA was sequenced with SP6 and T7 primers using the Perkin Elmer Big Dye kit and ABI 377 automatic sequencer.
Plasmid constructs
PML/RARA was subcloned in pCDNA3 (Invitrogen). Sitedirected mutagenesis of PML/RARA was performed using the PCR 'stitching' method. 23 The following 'internal' mutant primers (forward (primer1) and reverse (primer2)) were used to introduce the specific mutations; an in-phase stop codon in the ligand binding domain of PML/RARA at Gln 903. Primer 1; 5ЈGCCGCCTCTCATCTAGGAAATG3Ј; Primer 2, 5ЈCAT-TTCCTAGATGAGAGGCGGC 3Ј
Cell culture and transient transfection
NB4 sensitive and resistant cells were cultured as previously described. 19, 20 Briefly, cells were maintained at exponential growth in RPMI (Life Technology, Cergy, France) supplemented with 10% fetal calf serum, glutamine and penicillin/streptomycin at 37°C under 5% CO 2 atmosphere.
For transient transfection, HeLa cells were transfected using Lipofectamine Plus reagent (Life Technology) according to the manufacturer's instruction. Briefly, 4 l Lipofectamine was mixed with 2 g of DNA in serum-free DMEM medium and added to approximately 1 × 10 6 cells. After 3 h, medium supplemented with 20% FCS was added and cells were cultured overnight. Transfected cells were assayed for protein expression by western blotting and indirect immunofluorescence staining and used in the transcriptional activity assay.
Western blotting
Whole cell protein extracts (20 g) were separated on an 8% SDS-polyacrylamide gel and transferred on to nitrocellulose membranes (Amersham/Pharmacia Biotech). Membranes were blocked with 3% fat-free milk in PBS, before incubation with primary antibodies for 1 h at room temperature. Primary antibodies included the polyclonal antiserum directed against PML, 24 and polyclonal antisera directed against the F and D regions of RARA (both generously gifts from Prof P Chambon (IGBMC, France). Subsequently, membranes were incubated with an anti-rabbit peroxidase-conjugated secondary antibody in block solution (Dako, France). All incubation steps were followed by three washes for 10 min in PBS containing 0.1% Tween 20. Development was performed using ECL reagent (Amersham/Pharmacia Biotech, Les Ullis, France) according to the manufacturer's instruction.
Immunofluorescence staining and confocal analyses
Transfected cells were fixed in methanol at −20°C for 10 min and preblocked with block solution (PBS containing 0.1% TWEEN 20 and 10% foetal calf serum). PML/RARA and PML were detected with the polyclonal antiserum directed against PML. 24 FITC-coupled anti-rabbit antibody (Dako) was used as a second antibody and was incubated with cells for 30 min at room temperature. All incubations were followed by three washes in PBS followed by a final wash in PBS containing 0.05% Tween for 10 min. Preparations were examined by confocal laser scanning microscopy using an MRC 600 confocal microscope (BioRad, Ivry, France). Images were collected using an oil immersion lens (60×, NA I.4 plan Apochromat) and using excitation wave lengths of 488 nm (for FITC). Nuclei counter-stained with DAPI (blue channel).
Luciferase assay
For luciferase assay, cells were transfected with a total of 2 g DNA containing the RARE-TK-luciferase reporter vector, the expression vectors indicated in the Figure legends and empty vector to maintain a constant concentration of plasmid DNA. Luciferase assays were performed according to the specification of the manufacturer (Promega, Lyon, France).
Results
NB4-R2 cell line harbors a stop mutation in the RA binding domain of PML/RARA
PML/RARA mRNA from NB4-R2 cells was specifically isolated using Dynal magnetic beads (M-280 streptavidin) coupled to a biotinylated PML/RARA oligonucleotide (identical to the sequence at the recombination site). Oligonucleotides were designed to amplify the retinoic acid binding site and the F region of PML/RARA (see Materials and methods). The sequences of the amplified cDNA fragment show a C to T mutation in the codon 903 located in the ligand-binding domain of PML/RARA (Figure 1a) . This conversion generates an in-frame amber termination codon leading to the deletion of the terminal 52 amino acids which encompasses critical residues for RA binding and trans-activation. The NB4 cell line is known to contain two copies of the t(15;17) translocation. Additional sequencing profiles of different PCR products revealed that, in addition to the transcript harboring the C to T mutation, wild-type PML/RARA transcript is still present in the cDNA of the NB4-R2 cells, thus indicating that the NB4-R2 expresses both wild-type (PML/RARA) and mutated (named PML/RARA ⌬903 ) alleles. Also no other mutations were detected in amplification products.
Glutamine 903 of PML/RARA corresponds to Gln 411 of RARA (considering the RARA nomenclature) (Figure 1b) . A similar point mutation generating a stop codon at position 411 of RARA has been reported in the RA-resistant non-APL HL60 cell line (Figure 1b) . 25 This mutation in RARA, associated with a resistant phenotype, confers a trans-dominant negative activity with respect to the trans-activating function of normal RARA. 25 
PML/RARA and PML/RARA ⌬903 coexpressed in HeLa cells
The cDNA sequence analysis shows that NB4-R2 cells express two copies of PML/RARA: a wild-type and a mutated one. Therefore, the NB4-R2 cell line should express the two proLeukemia teins PML/RARA and PML/RARA ⌬903 . However, in this cell line we reported previously that PML/RARA (110 kDa) could not be detected by immunoblot analysis. 22 We tried to detect PML/RARA ⌬903 in NB4-R2 cells using different antibodies, taking into account that the F epitope is absent in the PML/RARA ⌬903 isoform. Using a PML specific polyclonal antibody or an antibody raised against the D region of RARA (see Materials and methods), we were unable to clearly detect any of the isoforms in the NB4-R2 cell line (data not shown).
To study the property of PML/RARA ⌬903 , we introduced the C to T mutation in a wild-type PML/RARA cDNA by sitedirected mutagenesis and subcloned it in a mammalian expression vector. PML/RARA and PML/RARA ⌬903 were transfected in HeLa cells and translation products analyzed by western blotting. The PML specific polyclonal antibody recognises both isoforms of PML/RARA (Figure 2a, lanes 1 and 2) . The PML/RARA ⌬903 protein shows a slightly faster mobility profile due to the loss of the C-terminal 52 amino acids. The same membrane was reprobed with an antibody specific to the F region of RARA. With this antibody, only the wild-type PML/RARA was detected (Figure 2a, lanes 5 and 6) , thus confirming the deletion of the C-terminal end of RARA. Using an antibody specific to the D region of RARA both PML/RARA isoforms were revealed (Figure 2a, lanes 9 and 10) . The two PML/RARA isoforms were coexpressed in Hela cells ( Figure  2a, lanes 3 and 11) .
In order to study the effect of expression of PML/RARA ⌬903 on PML nuclear body organisation, transfected HeLa cells were studied by indirect immunofluorescence. Transfected PML/RARA control gives the characteristic micropunctate nuclear staining observed in several previous transfection studies (Figure 2b) . 26 When transfected into HeLa cells, PML/RARA ⌬903 also produces a micropunctate pattern very similar to the one observed with PML/RARA protein ( Figure   2b ). This result suggests that the truncated PML/RARA ⌬903 is also capable of disrupting PML NBs.
PML/RARA ⌬903 exhibits dominant negative activity
PML/RARA functions as a transcriptionally active receptor in APL cells. We questioned whether the truncated PML/RARA mutant protein could exhibit dominant activity with respect to normal RARA or PML/RARA receptors. Transactivation analyses were carried out in HeLa cells using a luciferase reporter construct under the control of RARE and a basal thymidine kinase (tk) promoter. We observe an enhanced level of basal transcriptional activity in HeLa cells upon stimulation with 1 m ATRA (Figure 3, lane 1) indicating a transcriptional activity mediated by endogenous retinoic receptors. PML/RARA expression inhibits this endogenous activity but the inhibition is slightly reversed by the addition of ATRA ( Figure 3, lane 2) . In contrast, PML/RARA ⌬903 expression inhibits endogenous retinoic receptor activity but this inhibition is not reversed by the addition of ATRA (Figure 3 , lane 3).
To determine whether PML/RARA ⌬903 exerts a dominant negative repression on exogenous RARA or PML/RARA activity, cotransfection of RARA, PML/RARA and PML/RARA ⌬903 was performed (Figure 3, lanes 4 to 7) . We show that PML/RARA inhibits the exogenous transcriptional activity of RARA (Figure 3 , compare lanes 4 and 5) and that this dominant negative activity is also observed with PML/RARA ⌬903 (Figure 3, lane 6) . Moreover, the truncated PML/RARA ⌬903 retains its transcriptional inhibition activity under ATRA treatment. These results show that in contrast to wild-type PML/RARA, the mutant PML/RARA ⌬903 does not respond to ATRA treatment. To determine whether the mutated form of PML/RARA could repress the wild-type PML/RARA phenotype, we cotransfected both isoforms and assayed luciferase activity with and without ATRA. The assay shows that contransfection of PML/RARA and PML/RARA ⌬903 results in a PML/RARA ⌬903 phenotype which is not reversed by the addition of ATRA (Figure 3, lane 7) , further demonstrating that PML/RARA ⌬903 can act as a dominant negative receptor on PML/RARA.
Discussion
A molecular response to a drug can be studied by analyzing the mechanism leading to a drug resistant phenotype. The development of RA-resistant APL cell lines has two benefits: first, it allows the analysis of mechanisms by which RA induces APL cell differentiation; second, it furnishes a tool to address the problems associated with clinical ATRA resistance. It appears that in vitro, APL ATRA-resistance is mainly associated with defects in the RARA/E-domain of PML/RARA highlighting the role of the fusion protein in mediating the sensitivity to ATRA. In APL cells, several mutations conferring ATRA resistance have been described clustered in two regions. The first region susceptible to mutation is located in the middle part of the E-domain. Mutations described include the replacement of Arg272⌬Gln, Met297⌬Leu 17 and Leu290⌬Val 18 which are amino acids involved in forming the binding pocket for RA. 27 The second cluster susceptible to mutation is located in the carboxyl terminus of the E-domain; mutations detected include missense mutations of Arginine 394, Methionine 413, 18 Proline 407 16 and Leucine 398.
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Figure 3
Expression of the PML/RARA ⌬903 protein inhibits retinoic acid transcriptional activity. To assay for transcriptional activity of PML/RARA ⌬903 a LUC reporter plasmid containing the RARE retinoic acid response element of the RAR␤ 37 upstream of thymidine kinase promoter (RARE-tk-LUC) was used to assay the transcriptional activity of the PML/RARA mutant protein. The assay was performed with (+) or without (−) the presence of expression vectors containing the indicated receptors (the RARA, PML/RARA or PML/RARA ⌬903 ). The amount of plasmid was kept constant in all transfection assays and adjusted to 2 g using empty vectors. Luciferase activity was measured 48 h after the transfection. The results are shown without (black columns) or with 1 m ATRA treatment during 18 h (white columns). The value indicated is a mean of two independent transfections. These mutations affect amino acids implicated in RA binding. For example, Arg272 has been characterized to contribute to the hydrogen bond network between RA and its receptor 27 or Arg394 which is crucial for RA binding and transactivation of the RARA receptor. 28 Moreover, these mutations are localized near other codons; codon 391 or codons 406, 407 and 410 reportedly important for RARA function. 29, 30 We describe here a new mutation in codon 903 (codon 411 in the RARA nomenclature) in the E-domain of the RAR moiety of PML/RARA leading to the deletion of the C-terminal 52 amino acids. The region deleted by this mutation comprises four of the seven residues constituting the ␣-helix 12 which includes the AF2 part of the E-domain. This ␣-helix 12 appears to be crucial for RA binding and transcriptional activity. In the presence of RA the ␣-helix 12 of PML/RARA is repositioned, stabilizing the binding pocket for RA and providing a surface for coactivators to bind and thereby generates the transcriptional activity of the AF2 domain. 31 PML/RARA ⌬903 lacks half of ␣-helix 12 and we have demonstrated that PML/RARA ⌬903 can repress transcriptional activity but importantly this repression cannot be overcome upon ATRA treatment. It is tempting to speculate on the effect of a deletion in this helix. RA is able to bind to the truncated receptor but is not retained in the cavity because of the absence of the helix. The deletion in the ␣-helix 12 could abrogate the binding surface for coactivators and either lead to a lack of transactivation property or result in the constitutive binding of co-repressors. It has been Leukemia shown that deletion of the ␣-helix 12 of RARA leads to constitutive binding of the SMRT co-repressor. 32 Most interesting, in non-APL HL60 RA-resistant cell lines, a mutation similar to the PML/RARA ⌬903 mutation in NB4-R2 cells was reported independently by two groups in RARA. 25, 33 The fact that continuous exposure to ATRA selects clones with defects in PML/RARA (APL clone) and in RARA (non-APL clones), a phenotype due to an identical mutation in the same codon highlights the importance of this part of the molecule for ATRA response. Moreover, it appears that both mutants act as dominant-negative repressors on the corresponding wildtype allele. How could we explain this trans-dominant activity due to the deletion? It has been suggested that this trans-dominant activity occurs by the formation of heterodimers between the mutated RARA ⌬411 and wild-type RARA, thereby preventing transactivation by RA, or by the formation of heterodimers with RXR thus preventing its interaction with normal RARA. 25 PML/RARA is known to block the expression of RARAresponsive genes at a physiological dose of ATRA. At a therapeutic dose of ATRA, it has been suggested that PML/RARA could act as a transcriptional activator and/or could be degraded; in both cases transcription of critical genes for cell differentiation are then activated (for recent reviews see Refs 34 and 35) . We show here that PML/RARA ⌬903 exhibits dominant activity on PML, RARA and PMLRARA. PML/RARA ⌬903 which is sufficient to disrupt PML NBs or to block RA-responsive genes, is probably sufficient to also mediate the differentiation block.
In NB4-R2 cells, the messages coding for wild-type PML/RARA and PML/RARA ⌬903 are coexpressed, however, we can not determine whether the two isoforms are expressed, and if so in what proportion. Nevertheless, it is clear that in NB4-R2 cells, the level of wild-type PML/RARA protein is below what is detectable. 22 One explanation could be that in this cell line PML/RARA protein may be unstable or subject to degradation, independently of ATRA treatment. A similar situation was described by Fanelli et al 36 who show that retinoic acid resistance is mediated by a constitutive degradation of PML/RARA through the proteasome pathway.
In summary, the fact that NB4-R2 and HL60-R cells harbor the same point mutation (Gln codon 411/903) in the RARA gene, generating a truncated retinoid receptor, illustrates two exquisite cell systems for complementary investigations on retinoid resistance. Also, comparing function of the mutated RARA ⌬411 and the mutated PML/RARA ⌬903 should help to determine the contribution of the PML moiety in the alteration of the promyelocyte physiology (maturation and apoptosis). In keeping with this central question, our present findings on the function of PML/RARA ⌬903 reinforce our conclusion on a RARA-independent signalling pathway 'rexinoid', to rescue maturation in ATRA resistant APL cells. 38 
